Fortune February 1, 2024
Katrina Compoli, Bloomberg

WW International Inc. suffered its worst month on record in January, erasing the wellness company’s advance since it said in March that it was entering the growing market for a new class of weight-loss drugs.

WW, better known as WeightWatchers, slumped 6.1% on Wednesday, bringing its decline for the month to 57% amid emerging competition and concern around subscriber growth. The latest drop came as part of a broad market slide Wednesday after Federal Reserve Chair Jerome Powell signaled officials aren’t rushing to cut interest rates.

The performance is a stark reversal from 2023. The stock notched its biggest one-day gain since 2015 on March 7 after WW struck a deal for telehealth obesity-drug provider Sequence. Enthusiasm around the...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma, Pharma / Biotech, Provider, Wellness
From weight to wellness: New database could transform obesity research
5 Wellness Trends That Might Be Secretly Harming You—By A Psychologist
How Global Healthcare Systems are Integrating Mental Health and Wellness Services
A comparison of wellness practices across continents
Wearable Tech Is Changing Fitness—Here's How Studios Can Keep Up

Share This Article